Training Example: OCREVUS (Genentech) – Review the Data, Give Your Score & Compare to the Real AI Evaluation

[H3] It's your move. Ask about treating multiple sclerosis with
[H1] OCREVUS ZUNOVO®

Learn More
Watch TV Commercial

[H3] It's your move. Ask about treating multiple sclerosis with
[H1] OCREVUS ZUNOVO®

Learn More
Watch TV Commercial

[H3] 2-TIMES-A-YEAR* OCREVUS is AVAILABLE 2 WAYS for treating RMS and PPMS
*For OCREVUS [IV], your first dose will be split into 2, for a total of 3 treatments your first year.

[H3] ~10-minute†
subcutaneous injection

[IMG: OCREVUS ZUNOVO logo]

Learn More

[H3] 4-hour†/2-hour†‡
intravenous infusion

[IMG: OCREVUS logo]

Learn More

†This is only administration time and does not account for total treatment time. Actual clinic time may vary.
The duration of an infusion or injection could be longer should a reaction occur.
‡For eligible patients who have not previously experienced any serious infusion reactions with OCREVUS.

[H3] That's one reason over 450,000+ people have chosen OCREVUS treatments for their MS.§
§Globally as of October 2025.

[IMG: Icon of a desk calendar with]

See a side-by-side look at how OCREVUS ZUNOVO and OCREVUS® [IV]* are administered for treating relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).

Explore OCREVUS Options
*For OCREVUS [IV], your first dose will be split into 2, for a total of 3 treatments your first year.

[H2] “
There's more to me than MS, so
I choose ~10-minute†
OCREVUS ZUNOVO.
†This is only administration time and does not account for total treatment time. Actual clinic time may vary.

[H3] Connect with support and guidance
With OCREVUS CONNECTS® you can get help with all this:
Questions about MS and your treatment
Finding treatment location options to discuss with your healthcare provider, including information about treatment at home via health provider
Understanding insurance coverage
Financial assistance options for your treatment
Find out more about this program
Get Connected

[IMG: Photo of a woman holding up two fingers, labeled]

[H3] Proven to slow disability progression
OCREVUS ZUNOVO and OCREVUS were proven effective as compared with Rebif® in RMS and placebo in PPMS.

See All the Results

[IMG: Icon of a shoe walking]

[IMG: Photo of a woman sewing with a child, labeled]

[H3] What to know as you get started
Before starting any treatment, it's important to understand the possible risks, as well as the potential benefits. Learn about what to watch out for while taking OCREVUS and tell your healthcare provider right away if you experience any reactions.

Review Side Effects

Ocrevus® and Ocrevus Zunovo® are multiple sclerosis treatments that have been designed to reduce relapses in adult patients with relapsing MS (RMS) and to slow disability progression and reduce brain lesions in people with RMS and primary progressive MS (PPMS). They work by targeting and reducing specific B cells in the immune system that can cause inflammation and damage to the brain and spinal cord.
OCREVUS ZUNOVO is a ~10-minute subcutaneous injection given 2 times a year. Ocrevus Zunovo® is administered via a subcutaneous injection through a thin needle under the skin in the abdomen by a healthcare provider. If you take OCREVUS ZUNOVO, you will receive one (1) 920mg injection every 6 months, each lasting about 10 minutes. Before your first OCREVUS ZUNOVO injection, your healthcare provider or nurse will go over the injection process with you and answer any questions you may have. Your healthcare team will then monitor you closely in case you have an injection reaction.
Ocrevus® is a 2-4 hour infusion given 2 times a year. OCREVUS is an infusion therapy—also known as IV therapy—given as an intravenous infusion into a vein in your arm. If you take OCREVUS infusions, your first dose will be given as 2 separate 300 mg infusions 2 weeks apart, each lasting 2.5 hours. After your first dose, you will receive one (1) 600mg infusion every 6 months, each lasting 2 to 4 hours. Depending on what you and your doctor decide is right for you, you can receive your infusions at an infusion center, your doctor’s office, or at home.
Injection reactions are a common side effect of OCREVUS ZUNOVO, which can be serious and may require you to be hospitalized. You will be monitored for signs and symptoms of an injection reaction when you receive OCREVUS ZUNOVO. This will happen during all injections for at least 1 hour after your first injection, and for at least 15 minutes after all injections following the first injection. The most common symptoms of these infusion reactions are itchy skin, rash, hives, tiredness, coughing or wheezing, trouble breathing, throat irritation or pain, feeling faint, fever, redness on your face (flushing), nausea, headache, swelling of the throat dizziness, shortness of breath, fatigue, fast heartbeat, injection site pain, swelling and redness. These injection reactions can happen during or up to 24 hours after administration. It is important that you call your healthcare provider right away if you get any of the signs or symptoms listed above after each injection.
Infusion reactions are a common side effect of OCREVUS, which can be serious and may require you to be hospitalized. You will be monitored during your infusion and for at least 1 hour after each infusion of OCREVUS for signs and symptoms of an infusion reaction. The most common symptoms of these infusion reactions are itchy skin, rash, hives, tiredness, coughing or wheezing, trouble breathing, throat irritation or pain, feeling faint, fever, redness on your face (flushing), nausea, headache, swelling of the throat dizziness, shortness of breath, fatigue and a fast heart beat. These infusion reactions can happen for up to 24 hours after your infusion. It is important that you call your healthcare provider right away if you get any of the signs or symptoms listed above after each infusion. If you get infusion reactions, your healthcare provider may need to stop or slow down the rate of your infusion.

Back To Top

[H4]
Important Safety Information & Indications

Back to Top

What are OCREVUS and OCREVUS ZUNOVO?
OCREVUS and OCREVUS ZUNOVO are prescription medicines used to treat:
Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
Primary progressive MS, in adults.
It is not known if OCREVUS and OCREVUS ZUNOVO are safe and effective in children.

Who should not receive OCREVUS or OCREVUS ZUNOVO?
Do not receive OCREVUS or OCREVUS ZUNOVO if you:
have an active hepatitis B virus (HBV) infection.
have had a life-threatening administration reaction to ocrelizumab.
have had a life-threatening allergic reaction to ocrelizumab, hyaluronidase, or any of the ingredients of OCREVUS ZUNOVO. Tell your healthcare provider if you have had an allergic reaction to OCREVUS or OCREVUS ZUNOVO or any of their ingredients in the past.
What is the most important information I should know about OCREVUS and OCREVUS ZUNOVO?
OCREVUS and OCREVUS ZUNOVO can cause serious side effects, including:
Infusion reactions (OCREVUS): Infusion reactions are a common side effect of OCREVUS, which can be serious and may require you to be hospitalized. You will be monitored during your infusion and for at least 1 hour after each infusion of OCREVUS for signs and symptoms of an infusion reaction.
Injection reactions (OCREVUS ZUNOVO): Injection reactions are a common side effect of OCREVUS ZUNOVO, which can be serious and may require you to be hospitalized. You will be monitored for signs and symptoms of an injection reaction when you receive OCREVUS ZUNOVO. This will happen during all injections for at least 1 hour after your first injection, and for at least 15 minutes after all injections following the first injection.
Tell your healthcare provider or nurse if you get any of these symptoms:
itchy skin
rash
hives
tiredness
coughing or wheezing
trouble breathing
throat irritation or pain
feeling faint
fever
redness on your face (flushing)
nausea
headache
swelling of the throat
dizziness
shortness of breath
fatigue
fast heartbeat
Additionally, for OCREVUS ZUNOVO:
injection site pain
swelling
redness
These infusion and injection reactions can happen during or up to 24 hours after administration. It is important that you call your healthcare provider right away if you get any of the signs or symptoms listed above after each infusion or injection.
Infection:
Infections are a common side effect. OCREVUS and OCREVUS ZUNOVO increase your risk of getting upper respiratory tract infections, lower respiratory tract infections, skin infections, and herpes infections. Serious infections can happen with OCREVUS and OCREVUS ZUNOVO, which can be life-threatening or cause death. Tell your healthcare provider if you have an infection or have any of the following signs of infection including fever, chills, or a cough that does not go away, or painful urination. Signs of herpes infection include: cold sores, shingles, genital sores, skin rash, pain, and itching. Signs of more serious herpes infection include: changes in vision, eye redness or eye pain, severe or persistent headache, stiff neck, and confusion. Signs of infection can happen during treatment or after you have received your last dose of OCREVUS or OCREVUS ZUNOVO. Tell your healthcare provider right away if you have an infection. Your healthcare provider should delay your treatment with OCREVUS or OCREVUS ZUNOVO until your infection is gone.
Hepatitis B virus (HBV) reactivation: Before starting treatment with ocrelizumab, your healthcare provider will do blood tests to check for hepatitis B viral infection. If you have ever had hepatitis B virus infection, the hepatitis B virus may become active again during or after treatment with OCREVUS or OCREVUS ZUNOVO. Hepatitis B virus becoming active again (called reactivation) may cause serious liver problems including liver failure or death. Your healthcare provider will monitor you if you are at risk for hepatitis B virus reactivation during treatment and after you stop receiving OCREVUS or OCREVUS ZUNOVO.
Weakened immune system: OCREVUS or OCREVUS ZUNOVO taken before or after other medicines that weaken the immune system could increase your risk of getting infections.
Progressive Multifocal Leukoencephalopathy (PML): PML is a rare brain infection that usually leads to death or severe disability and has been reported with ocrelizumab. Symptoms of PML get worse over days to weeks. It is important that you call your healthcare provider right away if you have any new or worsening neurologic signs or symptoms that have lasted several days, including problems with:
thinking
eyesight
strength
balance
weakness on 1 side of your body
using your arms or legs
Decreased immunoglobulins: OCREVUS and OCREVUS ZUNOVO may cause a decrease in some types of antibodies. Your healthcare provider will do blood tests to check your blood immunoglobulin levels.
Before receiving OCREVUS or OCREVUS ZUNOVO, tell your healthcare provider about all of your medical conditions, including if you:
have or think you have an infection. See “What is the most important information I should know about OCREVUS and OCREVUS ZUNOVO?”
have ever taken, take, or plan to take medicines that affect your immune system, or other treatments for MS. These medicines could increase your risk of getting an infection.
have ever had hepatitis B or are a carrier of the hepatitis B virus.
have a history of inflammatory bowel disease or colitis.
have a history of liver problems.
have had a recent vaccination or are scheduled to receive any vaccinations.
You should receive any required ‘live’ or ‘live-attenuated’ vaccines at least 4 weeks before you start treatment with OCREVUS or OCREVUS ZUNOVO. You should not receive ‘live’ or ‘live-attenuated’ vaccines while you are being treated with OCREVUS or OCREVUS ZUNOVO and until your healthcare provider tells you that your immune system is no longer weakened.
When possible, you should receive any ‘non-live’ vaccines at least 2 weeks before you start treatment with OCREVUS or OCREVUS ZUNOVO. If you would like to receive any non-live (inactivated) vaccines, including the seasonal flu vaccine, while you are being treated with OCREVUS or OCREVUS ZUNOVO, talk to your healthcare provider.
If you have a baby and you received OCREVUS or OCREVUS ZUNOVO during your pregnancy, it is important to tell your baby’s healthcare provider about receiving OCREVUS or OCREVUS ZUNOVO so they can decide when your baby should be vaccinated.
are pregnant, think that you might be pregnant, or plan to become pregnant. It is not known if OCREVUS and OCREVUS ZUNOVO will harm your unborn baby. You should use birth control (contraception) during treatment with OCREVUS and OCREVUS ZUNOVO and for 6 months after your last dose of OCREVUS or OCREVUS ZUNOVO. Talk with your healthcare provider about what birth control method is right for you during this time. Tell your healthcare provider if you become pregnant while receiving OCREVUS or OCREVUS ZUNOVO.
are breastfeeding or plan to breastfeed. It is not known if OCREVUS and OCREVUS ZUNOVO pass into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take OCREVUS or OCREVUS ZUNOVO.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What are the possible side effects of OCREVUS and OCREVUS ZUNOVO?
OCREVUS and OCREVUS ZUNOVO may cause serious side effects, including:
Risk of cancers (malignancies) including breast cancer: Follow your healthcare provider’s instructions about standard screening guidelines for breast cancer.
Inflammation of the colon, or colitis: Tell your healthcare provider if you have any symptoms of colitis, such as:
Diarrhea (loose stools) or more frequent bowel movements than usual
Stools that are black, tarry, sticky or have blood or mucus
Severe stomach-area (abdomen) pain or tenderness
Liver damage. OCREVUS and OCREVUS ZUNOVO may cause liver damage. Your healthcare provider will do blood tests to check your liver before you start OCREVUS or OCREVUS ZUNOVO and while you take OCREVUS or OCREVUS ZUNOVO if needed. Tell your healthcare provider right away if you have any symptoms of liver damage, such as:
yellowing of the skin and eyes (jaundice)
nausea
vomiting
unusual darkening of the urine
feeling tired or weak
The most common side effects of OCREVUS ZUNOVO include:
Injection reactions
Respiratory tract infections
Skin infect

[H6] TREATMENT EXPERIENCE
[H4] What an appointment is like for
[H1] OCREVUS ZUNOVO or OCREVUS

[H6] TREATMENT EXPERIENCE
[H4] What an appointment is like for
[H1] OCREVUS ZUNOVO or OCREVUS

Quick Links

[H6] INJECTION EXPERIENCE
[H3] OCREVUS ZUNOVO is a ~10-minute subcutaneous injection* given 2 times a year†
Depending on what you and your doctor decide is right for you, you can receive your injection at an injection center, your doctor’s office, or at home. Watch this video to learn more about what to expect.
*This is only administration time and does not account for total treatment time. Actual clinic time may vary.
†For OCREVUS ZUNOVO, there is no split first dose.

[H3] Receiving your OCREVUS ZUNOVO injection
Before your first OCREVUS ZUNOVO injection, your healthcare provider or nurse will go over the injection process with you and answer any questions you may have. Then, while you’re receiving your injection, your healthcare team will monitor you closely from start to finish to ensure your comfort or in case you have an injection reaction.
[H4] Total appointment time for your injection: At least 55 min-1 hr 40 min

[IMG: Illustration of a woman taking a pill]

[H4] PRE-INJECTION: 30 MINUTES

You will take premedication at least 30 minutes before starting each OCREVUS ZUNOVO treatment, usually as pills to swallow
You may be able to take your medications at home—your healthcare team will advise on all pre-treatment protocols

[IMG: Illustration of an injection into a woman]

[H4] INJECTION: ~10 MINUTES

You will be asked to sit or lie down, and a thin needle will be inserted under the skin in your abdomen area. This needle will be connected to the prepared syringe containing OCREVUS ZUNOVO
A member of your healthcare team will either inject OCREVUS ZUNOVO manually or will use an automatic pump to do this

[IMG: Illustration of a woman looking at her phone while waiting in an armchair]

[H4] POST INJECTION: 15 MINUTES

Your healthcare team will observe you for at least one hour after your first injection. For all subsequent injections, you will be observed for at least 15 minutes
This will allow your healthcare team to watch out for any side effects related to your treatment

[H3] What to expect at your injection appointment
Watch Nurse Practitioner Yasmine walk you through what an OCREVUS ZUNOVO injection appointment is from start to finish.

[H6] INFUSION EXPERIENCE
[H3] OCREVUS is a 2-4 hour infusion* given 2 times a year†
OCREVUS is an infusion therapy—also known as IV therapy—given as an intravenous infusion into a vein in your arm. Depending on what you and your doctor decide is right for you, you can receive your infusions at an infusion center, your doctor’s office, or at home. Watch this video to learn more about what to expect.
*This is only administration time and does not account for total treatment time. Actual clinic time may vary.
†For OCREVUS, your first dose will be split into 2, for a total of 3 treatments your first year. After your first treatment, you will receive 1 infusion every 6 months, each lasting 2-4 hours.

[H3] Receiving your OCREVUS infusion
Before your first infusion, your healthcare provider or nurse will go over the infusion process with you and answer any questions you may have. Then, while you’re receiving your infusion, your healthcare team will monitor you closely from start to finish to ensure your comfort or in case you have an infusion reaction.
[H4] Total appointment time for your infusion: At least 3:30-6 hours

[IMG: Illustration of a doctor checking in on a female patient]

[H4] PRE-INFUSION: 30-60 MINUTES

You will be given premedication 30-60 minutes before starting your OCREVUS treatment to help reduce possible infusion reactions. This premedication is usually given as part of your IV infusion

[IMG: Illustration of a patient receiving an IV infusion]

[H4] INFUSION: 2-4 HOURS

You’ll be seated in a supportive chair. Once settled, a thin needle will be inserted into your arm to start the infusion of OCREVUS. An automatic pump will also be set up to ensure you receive the exact amount
If an infusion reaction occurs, your healthcare team may stop or slow the rate of your infusion

[IMG: Illustration of a woman reading a book while waiting in an armchair]

[H4] POST INFUSION: 1 HOUR

You may be asked to stay another hour for observation. This will allow your healthcare team to watch out for any side effects related to your treatment

[H3] You may be able to receive a shorter 2-hour‡ infusion
If you don’t experience any serious infusion reactions with the 4-hour OCREVUS infusion, your next infusion could take as little as 2 hours.§ It’s the same dose of OCREVUS, just given faster.
Ask your doctor if the shorter 2-hour OCREVUS infusion option is right for you.
‡This is only administration time and does not account for total treatment time. Actual clinic time may vary.
§The duration of an infusion could be longer should a reaction occur.

[H3] What to expect at your infusion appointment
Hear from John Kramer, PA, about what it's like to get an OCREVUS infusion. He's joined by some real people who choose OCREVUS who can tell you about their experiences.

[IMG: icon of a clipboard]

[H3] OCREVUS ZUNOVO and OCREVUS appointment checklist
Take your tablet, pack some snacks. Download our checklist for tips to help you prepare for your treatment.

Download the Checklist

[IMG: Photo of a woman at a nail salon, labeled]

[H3] Get all your questions answered with OCREVUS CONNECTS®
Call OCREVUS CONNECTS® (1-844-OCREVUS) for support throughout your treatment journey. We're happy to talk to you about everything from insurance and payment options to what to expect at your treatment. This no-cost service is available Monday through Friday, 9 AM to 8 PM ET, in English and Spanish.

[H6] TREATMENT REACTIONS
[H3] Make sure you understand the possible side effects
Infusion and injection reactions are a common side effect of OCREVUS and OCREVUS ZUNOVO, and can be serious and require you to be hospitalized. Most reactions are mild to moderate and treatable with treatment adjustments and medicines to help with the reactions. You will be monitored during your treatment for signs and symptoms of a reaction. Reactions are most common during and within an hour after treatment, but can occur up to 24 hours afterward.
[H4] Please tell your healthcare provider or nurse if you get any of these symptoms:
itchy skin
rash
hives
tiredness
coughing or wheezing
trouble breathing
throat irritation or pain
feeling faint
fever
redness on your face (flushing)
nausea
headache
swelling of the throat
dizziness
shortness of breath
fatigue
fast heartbeat
Additionally, for OCREVUS ZUNOVO: Injection site pain, swelling, or redness.
In a clinical study, injection reactions were more frequently reported with first injection. All reactions were mild to moderate, and treatable with treatment adjustments and medicines to help with reactions.

NEXT: OCREVUS CONNECTS®

Back To Top

[H4]
Important Safety Information & Indications

Back to Top

What are OCREVUS and OCREVUS ZUNOVO?
OCREVUS and OCREVUS ZUNOVO are prescription medicines used to treat:
Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
Primary progressive MS, in adults.
It is not known if OCREVUS and OCREVUS ZUNOVO are safe and effective in children.

Who should not receive OCREVUS or OCREVUS ZUNOVO?
Do not receive OCREVUS or OCREVUS ZUNOVO if you:
have an active hepatitis B virus (HBV) infection.
have had a life-threatening administration reaction to ocrelizumab.
have had a life-threatening allergic reaction to ocrelizumab, hyaluronidase, or any of the ingredients of OCREVUS ZUNOVO. Tell your healthcare provider if you have had an allergic reaction to OCREVUS or OCREVUS ZUNOVO or any of their ingredients in the past.
What is the most important information I should know about OCREVUS and OCREVUS ZUNOVO?
OCREVUS and OCREVUS ZUNOVO can cause serious side effects, including:
Infusion reactions (OCREVUS): Infusion reactions are a common side effect of OCREVUS, which can be serious and may require you to be hospitalized. You will be monitored during your infusion and for at least 1 hour after each infusion of OCREVUS for signs and symptoms of an infusion reaction.
Injection reactions (OCREVUS ZUNOVO): Injection reactions are a common side effect of OCREVUS ZUNOVO, which can be serious and may require you to be hospitalized. You will be monitored for signs and symptoms of an injection reaction when you receive OCREVUS ZUNOVO. This will happen during all injections for at least 1 hour after your first injection, and for at least 15 minutes after all injections following the first injection.
Tell your healthcare provider or nurse if you get any of these symptoms:
itchy skin
rash
hives
tiredness
coughing or wheezing
trouble breathing
throat irritation or pain
feeling faint
fever
redness on your face (flushing)
nausea
headache
swelling of the throat
dizziness
shortness of breath
fatigue
fast heartbeat
Additionally, for OCREVUS ZUNOVO:
injection site pain
swelling
redness
These infusion and injection reactions can happen during or up to 24 hours after administration. It is important that you call your healthcare provider right away if you get any of the signs or symptoms listed above after each infusion or injection.
Infection:
Infections are a common side effect. OCREVUS and OCREVUS ZUNOVO increase your risk of getting upper respiratory tract infections, lower respiratory tract infections, skin infections, and herpes infections. Serious infections can happen with OCREVUS and OCREVUS ZUNOVO, which can be life-threatening or cause death. Tell your healthcare provider if you have an infection or have any of the following signs of infection including fever, chills, or a cough that does not go away, or painful urination. Signs of herpes infection include: cold sores, shingles, genital sores, skin rash, pain, and itching. Signs of more serious herpes infection include: changes in vision, eye redness or eye pain, severe or persistent headache, stiff neck, and confusion. Signs of infection can happen during treatment or after you have received your last dose of OCREVUS or OCREVUS ZUNOVO. Tell your healthcare provider right away if you have an infection. Your healthcare provider should delay your treatment with OCREVUS or OCREVUS ZUNOVO until your infection is gone.
Hepatitis B virus (HBV) reactivation: Before starting treatment with ocrelizumab, your healthcare provider will do blood tests to check for hepatitis B viral infection. If you have ever had hepatitis B virus infection, the hepatitis B virus may become active again during or after treatment with OCREVUS or OCREVUS ZUNOVO. Hepatitis B virus becoming active again (called reactivation) may cause serious liver problems including liver failure or death. Your healthcare provider will monitor you if you are at risk for hepatitis B virus reactivation during treatment and after you stop receiving OCREVUS or OCREVUS ZUNOVO.
Weakened immune system: OCREVUS or OCREVUS ZUNOVO taken before or after other medicines that weaken the immune system could increase your risk of getting infections.
Progressive Multifocal Leukoencephalopathy (PML): PML is a rare brain infection that usually leads to death or severe disability and has been reported with ocrelizumab. Symptoms of PML get worse over days to weeks. It is important that you call your healthcare provider right away if you have any new or worsening neurologic signs or symptoms that have lasted several days, including problems with:
thinking
eyesight
strength
balance
weakness on 1 side of your body
using your arms or legs
Decreased immunoglobulins: OCREVUS and OCREVUS ZUNOVO may cause a decrease in some types of antibodies. Your healthcare provider will do blood tests to check your blood immunoglobulin levels.
Before receiving OCREVUS or OCREVUS ZUNOVO, tell your healthcare provider about all of your medical conditions, including if you:
have or think you have an infection. See “What is the most important information I should know about OCREVUS and OCREVUS ZUNOVO?”
have ever taken, take, or plan to take medicines that affect your immune system, or other treatments for MS. These medicines could increase your risk of getting an infection.
have ever had hepatitis B or are a carrier of the hepatitis B virus.
have a history of inflammatory bowel disease or colitis.
have a history of liver problems.
have had a recent vaccination or are scheduled to receive any vaccinations.
You should receive any required ‘live’ or ‘live-attenuated’ vaccines at least 4 weeks before you start treatment with OCREVUS or OCREVUS ZUNOVO. You should not receive ‘live’ or ‘live-attenuated’ vaccines while you are being treated with OCREVUS or OCREVUS ZUNOVO and until your healthcare provider tells you that your immune system is no longer weakened.
When possible, you should receive any ‘non-live’ vaccines at least 2 weeks before you start treatment with OCREVUS or OCREVUS ZUNOVO. If you would like to receive any non-live (inactivated) vaccines, including the seasonal flu vaccine, while you are being treated with OCREVUS or OCREVUS ZUNOVO, talk to your healthcare provider.
If you have a baby and you received OCREVUS or OCREVUS ZUNOVO during your pregnancy, it is important to tell your baby’s healthcare provider about receiving OCREVUS or OCREVUS ZUNOVO so they can decide when your baby should be vaccinated.
are pregnant, think that you might be pregnant, or plan to become pregnant. It is not known if OCREVUS and OCREVUS ZUNOVO will harm your unborn baby. You should use birth control (contraception) during treatment with OCREVUS and OCREVUS ZUNOVO and for 6 months after your last dose of OCREVUS or OCREVUS ZUNOVO. Talk with your healthcare provider about what birth control method is right for you during this time. Tell your healthcare provider if you become pregnant while receiving OCREVUS or OCREVUS ZUNOVO.
are breastfeeding or plan to breastfeed. It is not known if OCREVUS and OCREVUS ZUNOVO pass into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take OCREVUS or OCREVUS ZUNOVO.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What are the possible side effects of OCREVUS and OCREVUS

[H6] SAFETY & SIDE EFFECTS
[H4] What to know
[H1] OCREVUS ZUNOVO & OCREVUS safety

[H6] SAFETY & SIDE EFFECTS
[H4] What to know
[H1] OCREVUS ZUNOVO & OCREVUS safety

Quick Links

Before starting OCREVUS ZUNOVO or OCREVUS, you'll discuss the safety and side effects with your doctor—and together, decide if OCREVUS ZUNOVO or OCREVUS is an option for you.
[H3] What is the most important information I should know about OCREVUS ZUNOVO and OCREVUS?

[H6] POSSIBLE INJECTION REACTIONS
[H3] What are possible injection reactions?
Injection reactions are a common side effect of OCREVUS ZUNOVO, which can be serious and may require you to be hospitalized. You will be monitored for signs and symptoms of an injection reaction when you receive OCREVUS ZUNOVO. This will happen during all injections for at least 1 hour after your first injection, and for at least 15 minutes after all injections following the first injection.
Tell your healthcare provider or nurse if you get any of these symptoms:
itchy skin
rash
hives
tiredness
coughing or wheezing
trouble breathing
throat irritation or pain
feeling faint
fever
redness on your face (flushing)
nausea
headache
swelling of the throat
dizziness
shortness of breath
fatigue
fast heart beat
injection site pain
swelling
redness
These injection reactions can happen during or up to 24 hours after administration. It is important that you call your healthcare provider right away if you get any of the signs or symptoms listed above after each injection.
In a study, most of the reactions seen were mild (73%), such as a red bump with some pain, to moderate (27%), such as a slight fever. Your doctor can go into further details with you.

[H3] Real-world patient local injection site reactions*†

Local injection site reaction imagery

This is an example of what a local injection site reaction looks like with a real patient. All patients will respond differently.

[IMG: Photo of an injection site reaction in a patient]

IMMEDIATELY AFTER

[IMG: Photo of an injection site reaction in a patient]

30 MINUTES AFTER

[IMG: Photo of an injection site reaction in a patient]

1 HOUR AFTER

[IMG: Photo of an injection site reaction in a patient]

24 HOURS AFTER

[IMG: Photo of an injection site reaction in a patient]

48 HOURS AFTER

*Images are not indicative of the safety profile for OCREVUS ZUNOVO and do not encompass the full injection reaction experience. Systemic reactions are not shown here. Resolution occurred beyond 48 hours.
†Images unavailable beyond the timepoints shown.

[H6] POSSIBLE INFUSION REACTIONS
[H3] What are the possible infusion reactions?
Infusion reactions are a common side effect of OCREVUS, which can be serious and may require you to be hospitalized. You will be monitored during your infusion and for at least 1 hour after each infusion of OCREVUS for signs and symptoms of an infusion reaction. Tell your healthcare provider or nurse if you get any of these symptoms:
itchy skin
rash
hives
tiredness
coughing or wheezing
trouble breathing
throat irritation or pain
feeling faint
fever
redness on your face (flushing)
nausea
headache
swelling of the throat
dizziness
shortness of breath
fatigue
fast heart beat
These infusion reactions can happen for up to 24 hours after your infusion. It is important that you call your healthcare provider right away if you get any of the signs or symptoms listed above after each infusion. If you get infusion reactions, your healthcare provider may need to stop or slow down the rate of your infusion.

[H6] IMPORTANT INFORMATION

Does OCREVUS or OCREVUS ZUNOVO increase my risk of infection?

Infections are a common side effect. OCREVUS and OCREVUS ZUNOVO increase your risk of getting upper respiratory tract infections, lower respiratory tract infections, skin infections, and herpes infections. Serious infections can happen with OCREVUS and OCREVUS ZUNOVO, which can be life-threatening or cause death. Tell your healthcare provider if you have an infection or have any of the following signs of infection including fever, chills, or a cough that does not go away, or painful urination. Signs of herpes infection include: cold sores, shingles, genital sores, skin rash, pain, and itching. Signs of more serious herpes infection include: changes in vision, eye redness or eye pain, severe or persistent headache, stiff neck, and confusion. Signs of infection can happen during treatment or after you have received your last dose of OCREVUS or OCREVUS ZUNOVO. Tell your healthcare provider right away if you have an infection. Your healthcare provider should delay your treatment with OCREVUS or OCREVUS ZUNOVO until your infection is gone.
Hepatitis B virus (HBV) reactivation: Before starting treatment with ocrelizumab, your healthcare provider will do blood tests to check for hepatitis B viral infection. If you have ever had hepatitis B virus infection, the hepatitis B virus may become active again during or after treatment with OCREVUS or OCREVUS ZUNOVO. Hepatitis B virus becoming active again (called reactivation) may cause serious liver problems including liver failure or death. Your healthcare provider will monitor you if you are at risk for hepatitis B virus reactivation during treatment and after you stop receiving OCREVUS or OCREVUS ZUNOVO.
Weakened immune system: OCREVUS or OCREVUS ZUNOVO taken before or after other medicines that weaken the immune system could increase your risk of getting infections.
See below for risk information about Progressive Multifocal Leukoencephalopathy (PML).

What is the risk of Progressive Multifocal Leukoencephalopathy (PML)?

Progressive Multifocal Leukoencephalopathy (PML): PML is a rare brain infection that usually leads to death or severe disability, and has been reported with ocrelizumab. Symptoms of PML get worse over days to weeks. It is important that you call your healthcare provider right away if you have any new or worsening neurologic signs or symptoms that have lasted several days, including problems with:
thinking
eyesight
strength
balance
weakness on 1 side of your body
using your arms or legs

Who should not receive OCREVUS or OCREVUS ZUNOVO?

Do not receive OCREVUS or OCREVUS ZUNOVO if you:
have an active hepatitis B virus (HBV) infection.
have had a life-threatening administration reaction to ocrelizumab.
have had a life-threatening allergic reaction to ocrelizumab, hyaluronidase, or any of the ingredients of OCREVUS ZUNOVO. Tell your healthcare provider if you have had an allergic reaction to OCREVUS or OCREVUS ZUNOVO or any of their ingredients in the past.

What are the other possible risks of taking OCREVUS and OCREVUS ZUNOVO?

Decreased immunoglobulins: OCREVUS and OCREVUS ZUNOVO may cause a decrease in some types of antibodies. Your healthcare provider will do blood tests to check your blood immunoglobulin levels.
Another possible serious side effect of OCREVUS and OCREVUS ZUNOVO is an increased risk of cancers (malignancies), including breast cancer.
Breast cancer in clinical trials for OCREVUS
In 3 main clinical trials, 6* out of 781 females (<1%) were diagnosed with breast cancer. There were no cases of breast cancer reported in the trial period for patients taking REBIF or placebo.
*2 relapsing MS and 4 PPMS patients.
The FDA recommends that patients taking OCREVUS and OCREVUS ZUNOVO should follow standard breast cancer screening guidelines.
What you can do
Talk to your healthcare provider about the risk of breast cancer with OCREVUS and OCREVUS ZUNOVO and the risks and benefits of screening
For example, the American Cancer Society recommends:
Age 40-44 – Annual mammogram if you and your healthcare provider feel it’s appropriate
Age 45-54 – Annual mammogram recommended
Age 55+ – Mammogram every 2 years or annually, depending on what you and your healthcare provider feel is appropriate
Women under 40 with risk factors for breast cancer (genetic or environmental) should ask their HCP whether mammograms are advisable and how often to have them
Other screening guidelines from federally recognized sources (eg, the US Preventive Services Task Force, the Centers for Disease Control and Prevention) may be used based on HCP preference
Inflammation of the colon, or colitis: Tell your healthcare provider if you have any symptoms of colitis, such as diarrhea (loose stools) or more frequent bowel movements than usual, stools that are black, tarry, sticky or have blood or mucus, and severe stomach-area (abdomen) pain or tenderness.
Liver damage: OCREVUS and OCREVUS ZUNOVO may cause liver damage. Your healthcare provider will do blood tests to check your liver before you start OCREVUS or OCREVUS ZUNOVO and while you take OCREVUS or OCREVUS ZUNOVO if needed. Tell your healthcare provider right away if you have any symptoms of liver damage, such as: yellowing of the skin and eyes (jaundice), nausea, vomiting, unusual darkening of the urine, and feeling tired or weak.

What should I tell my physician before taking OCREVUS or OCREVUS ZUNOVO?

Before receiving OCREVUS or OCREVUS ZUNOVO, tell your healthcare provider about all of your medical conditions, including if you:
have or think you have an infection. See “What is the most important information I should know about OCREVUS and OCREVUS ZUNOVO?” in the OCREVUS Medication Guide and OCREVUS ZUNOVO Medication Guide.
have ever taken, take, or plan to take medicines that affect your immune system, or other treatments for MS. These medicines could increase your risk of getting an infection.
have ever had hepatitis B or are a carrier of the hepatitis B virus.
have a history of inflammatory bowel disease or colitis.
have a history of liver problems.
have had a recent vaccination or are scheduled to receive any vaccinations.
You should receive any required ‘live’ or ‘live-attenuated’ vaccines at least 4 weeks before you start treatment with OCREVUS or OCREVUS ZUNOVO. You should not receive ‘live’ or ‘live-attenuated’ vaccines while you are being treated with OCREVUS or OCREVUS ZUNOVO and until your healthcare provider tells you that your immune system is no longer weakened.
When possible, you should receive any ‘non-live’ vaccines at least 2 weeks before you start treatment with OCREVUS or OCREVUS ZUNOVO. If you would like to receive any non-live (inactivated) vaccines, including the seasonal flu vaccine, while you are being treated with OCREVUS or OCREVUS ZUNOVO, talk to your healthcare provider.
If you have a baby and you received OCREVUS or OCREVUS ZUNOVO during your pregnancy, it is important to tell your baby’s healthcare provider about receiving OCREVUS or OCREVUS ZUNOVO so they can decide when your baby should be vaccinated.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Is it safe to take OCREVUS or OCREVUS ZUNOVO if I am pregnant or breastfeeding?

You should talk to your healthcare provider before receiving OCREVUS or OCREVUS ZUNOVO if you:
are pregnant, think that you might be pregnant, or plan to become pregnant. It is not known if OCREVUS and OCREVUS ZUNOVO will harm your unborn baby. You should use birth control (contraception) during treatment with OCREVUS and OCREVUS ZUNOVO and for 6 months after your last dose of OCREVUS or OCREVUS ZUNOVO. Talk with your healthcare provider about what birth control method is right for you during this time. Tell your healthcare provider if you become pregnant while receiving OCREVUS or OCREVUS ZUNOVO.
are breastfeeding or plan to breastfeed. It is not known if OCREVUS and OCREVUS ZUNOVO pass into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take OCREVUS or OCREVUS ZUNOVO.
Data is available on pregnancy and lactation. Please reach out to your doctor to learn more.

[H4] “
After telling me the pros and cons, my doctor asked me what I thought. I said, ‘Okay—let’s do this.’
LEANN

Using OCREVUS ZUNOVO

[IMG: Illustration of a question mark in a circle]

[H3] Have additional questions or concerns?
Contact OCREVUS CONNECTS® at 1-844-OCREVUS (1-844-627-3887).
Support is available Monday through Friday, 9 AM to 8 PM ET.

NEXT: Connect to Support

Stuifbergen A, Becker H, Phillips C, Horton S, Morrison J, Perez F. Experiences of African American Women with Multiple Sclerosis. Int J MS Care. 2021;23(2):59-65.

Stuifbergen A, Becker H, Phillips C, Horton S, Morrison J, Perez F. Experiences of African American Women with Multiple Sclerosis. Int J MS Care. 2021;23(2):59-65.

Langer-Gould AM, Gonzales EG, Smith JB, Li BH, Nelson LM. Racial and Ethnic Disparities in Multiple Sclerosis Prevalence. Neurology. 2022;98(18):e1818-e1827.

Langer-Gould AM, Gonzales EG, Smith JB, Li BH, Nelson LM. Racial and Ethnic Disparities in Multiple Sclerosis Prevalence. Neurology. 2022;98(18):e1818-e1827.

Okai AF, Howard AM, Williams MJ, et al. Advancing Care and Outcomes for African American Patients With Multiple Sclerosis. Neurology. 2022;98(24):1015​-1020.

Okai AF, Howard AM, Williams MJ, et al. Advancing Care and Outcomes for African American Patients With Multiple Sclerosis. Neurology. 2022;98(24):1015​-1020.

Amezcua L, McCauley JL. Race and ethnicity on MS presentation and disease course. Mult Scler. 2020;26(5):561​-567.

Amezcua L, McCauley JL. Race and ethnicity on MS presentation and disease course. Mult Scler. 2020;26(5):561​-567.

Ingram M, Leih R, Adkins A, Sonmez E, Yetman E. Health Disparities, Transportation Equity and Complete Streets: a Case Study of a Policy Development Process through the Lens of Critical Race Theory. J Urban Health. 2020;97(6):876​-886.

Ingram M, Leih R, Adkins A, Sonmez E, Yetman E. Health Disparities, Transportation Equity and Complete Streets: a Case Study of a Policy Development Process through the Lens of Critical Race Theory. J Urban Health. 2020;97(6):876​-886.

Sohn H. Racial and Ethnic Disparities in Health Insurance Coverage: Dynamics of Gaining and Losing Coverage over the Life-Course. Popul Res Policy Rev. 2017;36(2):181​-201.

Sohn H. Racial and Ethnic Disparities in Health Insurance Coverage: Dynamics of Gaining and Losing Coverage over the Life-Course. Popul Res Policy Rev. 2017;36(2):181​-201.

Taylor J. Racism, Inequality, and Health Care for African Americans. The Century Foundation. December 19, 2019. Accessed April 16, 2023. https://tcf.org/content/report/racism-inequality-health-car

[H6] RESULTS IN RMS
[H1] Proven effective
[H4] for relapsing forms of MS

[H6] RESULTS IN RMS
[H1] Proven effective
[H4] for relapsing forms of MS

Quick Links

[H3] OCREVUS reduced relapses and slowed disability progression in relapsing MS
In 2 large, identical clinical studies over 2 years, OCREVUS was proven effective against Rebif®,* a currently approved treatment for relapsing MS, not a placebo. A placebo is a substance or treatment that has no active medicine.
*Rebif® is a registered trademark of EMD Serono, Inc.

[H3] Clinical study by the numbers

[IMG: Icon of a magnifying glass]

[H4] People included in the study:
1656 people (827 received OCREVUS, 829 received Rebif)
18–55 years of age
Average time since diagnosis was about 4 years
Had experienced ≥2 relapses in last 2 years, or ≥1 relapse in last year
Had T1 gadolinium-enhancing (Gd+) lesions and/or T2 hyperintense lesions

[IMG: Icon of an open book]

[H4] Why this is important:
Studied in a large number of people with relapsing MS
Studied in a range of people with MS
Studied in people who had active disease
Learn more about how OCREVUS ZUNOVO was studied

[H6] RELAPSES
[H3] OCREVUS reduced relapses

[H4] OCREVUS cut relapses nearly in half

[IMG: Icon of an arrow pointing down, with text reading]

[H4] More people taking OCREVUS had no relapses

[IMG: Icon of a bar chart showing decline, with text reading]

Results were consistent with Study 2

[H3] OCREVUS has 10+ years of results
Experience matters when treating your MS.
OCREVUS was proven effective against Rebif in a 2-year study. At the end of the study, patients could either continue with OCREVUS or switch to OCREVUS from Rebif, and continue to be observed for an additional 8+ years. The OCREVUS study examined patients over 10+ years. Talk to your doctor to find out more about the study results.

[H6] DISABILITY PROGRESSION
[H3] OCREVUS was proven effective at slowing disability progression compared with Rebif across 2 years

[IMG: Icon of an arrow pointing down, with text reading]

[IMG: 9.8% of people taking OCREVUS had disability progression compared with 15.2% of people taking Rebif]

†Disability progression was confirmed 3 months after the initial neurological change.
‡Disability progression was also confirmed after 6 months.

[H3] What is disability progression and why does it matter?
Disability progression is the increase in physical disability that happens over time for people with MS. How and when it happens is different for everyone. It can also vary in severity.
Some people may find they struggle with walking or remembering their “to-do” list. Others may experience tingling or numbness or blurred vision. While some may dismiss or overlook these symptoms—particularly if they are mild—they may be a sign of disability progression.

[H3] How is disability progression measured in clinical studies?
Disability progression is measured using a tool called the Expanded Disability Status Scale (EDSS). It assesses your functionality or changes to function in the areas listed below. OCREVUS was not proven to individually reduce each of these measured endpoints.

[IMG: Icon of an eye]

Visual functions - problems with sight or involuntary eye movements

[IMG: Icon of a person with a cane hunched over in pain]

Muscle weakness or difficulty moving limbs and walking

[IMG: Icon of a brain with a question mark]

Cerebral functions - problems with thinking or memory

[IMG: Icon of a shaking hand]

Tremor or loss of coordination

[IMG: Icon of a hand with the fingertips highlighted]

Numbness or loss of sensations

[IMG: Icon of a stomach with an exclamation point]

Bowel or bladder function

[IMG: Icon of a head with highlighted neck]

Problems with speech or swallowing

33%

[H3] More people showed disability improvements after 3 months with OCREVUS
33% more people taking OCREVUS had confirmed disability improvement compared with those taking Rebif®. Disability improvement was also measured using the EDSS and was confirmed after 3 months.§
§Disability improvement was not confirmed after 6 months.

[H3] Select Important Safety Information
Infusion reactions are a common side effect of OCREVUS, which can be serious and may require you to be hospitalized. You will be monitored during your infusion and for at least 1 hour after each infusion of OCREVUS for signs and symptoms of an infusion reaction. Tell your healthcare provider or nurse if you get any reactions. Please visit Safety & Side Effects for more information.

[H6] BRAIN LESIONS
[H3] OCREVUS was proven to reduce brain lesions on MRI
OCREVUS was consistently proven superior at reducing T1 Gd+ lesions‖ compared with Rebif across 2 clinical studies.
[H4] Near complete suppression¶ of T1 gadolinium-enhancing (Gd+) lesions‖

[IMG: Icons of a brain and an arrow pointing down, with text reading]

The average number of T1 Gd+ lesions per MRI was lower for OCREVUS:
Study 1: 0.016 lesions with OCREVUS compared with 0.286 lesions with Rebif
Study 2: 0.021 lesions with OCREVUS compared with 0.416 lesions with Rebif
‖A T1 gadolinium-enhancing (Gd+) lesion is a magnetic resonance imaging (MRI) indicator that highlights active inflammation has occurred. Active inflammation means that myelin is being damaged or destroyed. T1 Gd+ lesions are thought to be a sign of active inflammation.
¶The exact way OCREVUS works is not fully known.
[H4] Why is this important?
While you may not see them, MS can cause lesions to develop in the central nervous system (CNS). Over time, if these lesions progress, some of them may lead to a variety of symptoms that may be more noticeable. Reducing the development of new lesions is an important step in slowing MS progression.

[H6] OCREVUS ZUNOVO CLINICAL STUDY

[H3] The similarity of OCREVUS ZUNOVO subcutaneous injections to OCREVUS infusions was confirmed in a separate study.
This study measured the amount of medicine in the bloodstream, which is commonly done to check that the injection works like infusion. The results of the study showed there were no clinically significant differences between OCREVUS ZUNOVO and OCREVUS.

[H3] Now that I’ve seen the results, what’s next?
After reviewing the results and safety, having an honest conversation with your doctor is the next step. Our Doctor Discussion Guide can help shape the conversation around your symptoms, lifestyle, and goals so that you might find a treatment that is right for you.
Click below to either create a personalized list of questions to ask at your appointment or view a guide with commonly asked questions.

Personalize My Guide

View Common Questions

[IMG: Icons of a needle and syringe next to an IV bag]

[H3] What is the treatment experience like with OCREVUS ZUNOVO or OCREVUS?
Whether you’re getting OCREVUS ZUNOVO injections or OCREVUS infusions, both treatment options are just 2 times a year.# Your treatment may be given at an infusion center, your doctor’s office, or at home depending on what you and your doctor decide is right for you. Find out more about what to expect at your treatment appointment.

NEXT: Treatment Experience
#First treatment will be split into 2, for a total of 3 treatments the first year.

Back To Top

[H4]
Important Safety Information & Indications

Back to Top

What are OCREVUS and OCREVUS ZUNOVO?
OCREVUS and OCREVUS ZUNOVO are prescription medicines used to treat:
Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
Primary progressive MS, in adults.
It is not known if OCREVUS and OCREVUS ZUNOVO are safe and effective in children.

Who should not receive OCREVUS or OCREVUS ZUNOVO?
Do not receive OCREVUS or OCREVUS ZUNOVO if you:
have an active hepatitis B virus (HBV) infection.
have had a life-threatening administration reaction to ocrelizumab.
have had a life-threatening allergic reaction to ocrelizumab, hyaluronidase, or any of the ingredients of OCREVUS ZUNOVO. Tell your healthcare provider if you have had an allergic reaction to OCREVUS or OCREVUS ZUNOVO or any of their ingredients in the past.
What is the most important information I should know about OCREVUS and OCREVUS ZUNOVO?
OCREVUS and OCREVUS ZUNOVO can cause serious side effects, including:
Infusion reactions (OCREVUS): Infusion reactions are a common side effect of OCREVUS, which can be serious and may require you to be hospitalized. You will be monitored during your infusion and for at least 1 hour after each infusion of OCREVUS for signs and symptoms of an infusion reaction.
Injection reactions (OCREVUS ZUNOVO): Injection reactions are a common side effect of OCREVUS ZUNOVO, which can be serious and may require you to be hospitalized. You will be monitored for signs and symptoms of an injection reaction when you receive OCREVUS ZUNOVO. This will happen during all injections for at least 1 hour after your first injection, and for at least 15 minutes after all injections following the first injection.
Tell your healthcare provider or nurse if you get any of these symptoms:
itchy skin
rash
hives
tiredness
coughing or wheezing
trouble breathing
throat irritation or pain
feeling faint
fever
redness on your face (flushing)
nausea
headache
swelling of the throat
dizziness
shortness of breath
fatigue
fast heartbeat
Additionally, for OCREVUS ZUNOVO:
injection site pain
swelling
redness
These infusion and injection reactions can happen during or up to 24 hours after administration. It is important that you call your healthcare provider right away if you get any of the signs or symptoms listed above after each infusion or injection.
Infection:
Infections are a common side effect. OCREVUS and OCREVUS ZUNOVO increase your risk of getting upper respiratory tract infections, lower respiratory tract infections, skin infections, and herpes infections. Serious infections can happen with OCREVUS and OCREVUS ZUNOVO, which can be life-threatening or cause death. Tell your healthcare provider if you have an infection or have any of the following signs of infection including fever, chills, or a cough that does not go away, or painful urination. Signs of herpes infection include: cold sores, shingles, genital sores, skin rash, pain, and itching. Signs of more serious herpes infection include: changes in vision, eye redness or eye pain, severe or persistent headache, stiff neck, and confusion. Signs of infection can happen during treatment or after you have received your last dose of OCREVUS or OCREVUS ZUNOVO. Tell your healthcare provider right away if you have an infection. Your healthcare provider should delay your treatment with OCREVUS or OCREVUS ZUNOVO until your infection is gone.
Hepatitis B virus (HBV) reactivation: Before starting treatment with ocrelizumab, your healthcare provider will do blood tests to check for hepatitis B viral infection. If you have ever had hepatitis B virus infection, the hepatitis B virus may become active again during or after treatment with OCREVUS or OCREVUS ZUNOVO. Hepatitis B virus becoming active again (called reactivation) may cause serious liver problems including liver failure or death. Your healthcare provider will monitor you if you are at risk for hepatitis B virus reactivation during treatment and after you stop receiving OCREVUS or OCREVUS ZUNOVO.
Weakened immune system: OCREVUS or OCREVUS ZUNOVO taken before or after other medicines that weaken the immune system could increase your risk of getting infections.
Progressive Multifocal Leukoencephalopathy (PML): PML is a rare brain infection that usually leads to death or severe disability and has been reported with ocrelizumab. Symptoms of PML get worse over days to weeks. It is important that you call your healthcare provider right away if you have any new or worsening neurologic signs or symptoms that have lasted several days, including problems with:
thinking
eyesight
strength
balance
weakness on 1 side of your body
using your arms or legs
Decreased immunoglobulins: OCREVUS and OCREVUS ZUNOVO may cause a decrease in some types of antibodies. Your healthcare provider will do blood tests to check your blood immunoglobulin levels.
Before receiving OCREVUS or OCREVUS ZUNOVO, tell your healthcare provider about all of your medical conditions, including if you:
have or think you have an infection. See “What is the most important information I should know about OCREVUS and OCREVUS ZUNOVO?”
have ever taken, take, or plan to take medicines that affect your immune system, or other treatments for MS. These medicines could increase your risk of getting an infection.
have ever had hepatitis B or are a carrier of the hepatitis B virus.
have a history of inflammatory bowel disease or colitis.
have a history of liver problems.
have had a recent vaccination or are scheduled to receive any vaccinations.
You should receive any required ‘live’ or ‘live-attenuated’ vaccines at least 4 weeks before you start treatment with OCREVUS or OCREVUS ZUNOVO. You should not receive ‘live’ or ‘live-attenuated’ vaccines while you are being treated with OCREVUS or OCREVUS ZUNOVO and until your healthcare provider tells you that your immune system is no longer weakened.
When possible, you should receive any ‘non-live’ vaccines at least 2 weeks before you start treatment with OCREVUS or OCREVUS ZUNOVO. If you would like to receive any non-live (inactivated) vaccines, including the seasonal flu vaccine, while you are being treated with OCREVUS or OCREVUS ZUNOVO, talk to your healthcare provider.
If you have a baby and you received OCREVUS or OCREVUS ZUNOVO during your pregnancy, it is important to tell your baby’s healthcare provider about receiving OCREVUS or OCREVUS ZUNOVO so they can decide when your baby should be vaccinated.
are pregnant, think that you might be pregnant, or plan to become pregnant. It is not known if OCREVUS and OCREVUS ZUNOVO will harm your unborn baby. You should use birth control (contraception) during treatment with OCREVUS and OCREVUS ZUNOVO and for 6 months after your last dose of OCREVUS or OCREVUS ZUNOVO. Talk with your healthcare provider about what birth control method is right for you during this time. Tell your healthcare provider if you become pregnant while receiving OCREVUS or OCREVUS ZUNOVO.
are breastfeeding or plan to breastfeed. It is not known if OCREV